Results6 Oct 2026 · Tue morning
METROPOLISMetropolis Healthcare
Metropolis Healthcare reports about 15% revenue growth in its September-quarter update
Metropolis Healthcare's provisional update shows revenue up about 15% year on year, with double-digit growth in patient and test volumes and higher EBITDA margins.
Price, Monday's close₹553.60▲ 2.92%
Last 4 days
52-week low ₹412.2552-week high ₹609.05
- Sector
- Diagnostics
What happened
- Revenue grew about 15% year on year in the quarter, helped by double-digit growth in patient and test volumes, according to Sahi and Whalesbook.
- The reports name the TruHealth wellness and specialty diagnostics segments as the fastest-growing.
- EBITDA margins were higher both year on year and from the previous quarter, per the same reports.
- Revenue growth was 16.6% in the June quarter, when revenue was ₹450.2 crore. The company said the detailed results will follow board approval.
Why it matters
Good to know: EBITDA is earnings before interest, tax, depreciation and amortisation, a measure of operating profit. A provisional update gives headline figures before the board approves full results.
Key facts
- Revenue growth
- About 15% YoY (provisional)
- Volumes
- Double-digit growth in patients and tests
- June-quarter revenue growth
- 16.6% (₹450.2 crore)
Read the source
This is a summary of public news about Metropolis Healthcare, for information only. It is not a recommendation to buy, sell or hold METROPOLIS.